On June 3 Beijing time, longevity biotech startup NewLimit announced a $435 million Series C round led by Peter Thiel's Founders Fund, with participation from new investors Thrive Capital, Greenoaks, and Quiet Capital, alongside returning backers Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, and Valor Equity Partners. The round values NewLimit at $3.1 billion — more than triple its valuation a year ago, according to The Wall Street Journal. NewLimit stated that it is now moving its longevity medicine into human clinical trials, with its first drug, aimed at alcohol-related liver disease, expected to begin trials next year. The company emphasized that by reprogramming cell age, humanity is closer than ever to extending healthy lifespan and even slowing or reversing aging.
From Crypto Exchange to Longevity Lab
NewLimit was founded in 2021 by Coinbase co-founder and CEO Brian Armstrong, former GV partner and bioengineer Blake Byers, and stem cell biologist Jacob Kimmel, who together contributed $110 million to launch the venture in South San Francisco. Armstrong is best known for building the Nasdaq-listed cryptocurrency exchange Coinbase, but his interest in life sciences runs deep. Prior to this Series C, NewLimit had already completed three funding rounds, steadily assembling a drug discovery platform centered on cellular reprogramming. In its official mission statement, NewLimit declares: ‘We are developing the first medicines to restore youthful function to aging cells.’ Put simply, the company is pursuing the age-old dream of extended youth through rigorous science.
Yamanaka Factors: The Nobel Prize-Winning Key to Cell Rejuvenation
NewLimit's scientific foundation traces back to 2006, when Japanese researcher Shinya Yamanaka demonstrated that adult cells could be reprogrammed into an embryonic stem cell-like state simply by activating a handful of transcription factors. These ‘Yamanaka Factors’ shattered the dogma that cellular aging is irreversible, earning Yamanaka the 2012 Nobel Prize in Physiology or Medicine. NewLimit aims to translate this insight into medicines by delivering drugs that activate specific transcription factor genes, effectively resetting the epigenome to a younger configuration. However, the central challenge remains: which exact combination of transcription factors is needed to rejuvenate each different cell type? Identifying these effective genetic payloads is the company’s core R&D puzzle.
NewLimit’s website explains the rationale clearly: ‘As we age, our cells decline in function, making us more susceptible to disease. Aging was once thought to be inevitable, but emerging science shows it can be reversed at the cellular level. We are building on these discoveries to develop the first drugs that restore youthful function to aging cells.’ In essence, NewLimit is using science to pursue what many would call biological immortality.
To tackle this formidable challenge, NewLimit has chosen a pragmatic path: start with one specific disease. Its lead candidate targets alcohol-related liver disease, with clinical trials slated for next year. Co-founder Jacob Kimmel describes liver disease as ‘accelerated aging’ — it mirrors the universal aging process but in a faster, more extreme fashion. By securing regulatory approval in a well-defined indication, NewLimit hopes to later broaden its therapies to a wide range of age-related conditions, with the ultimate goal of slowing human aging itself.
The Billionaire Race Against Mortality
NewLimit is far from alone in the longevity space. In 2022, Sam Altman invested $180 million into Retro Biosciences, which is developing drugs to rejuvenate aging cells; the company recently disclosed a valuation of $1.8 billion. Also in 2022, Altos Labs launched with $3 billion in backing linked to Jeff Bezos, and has since raised nearly double that amount. From Thiel to Altman to Bezos, an elite tier of tech moguls is placing enormous bets on the science of slowing aging.
Peter Thiel has long been vocal about his disdain for death, calling it ‘the greatest enemy of humanity’ and lamenting that society accepts it as a natural law. For billionaires who have already conquered financial and technological frontiers, time is the only truly scarce resource — a luxury that money alone cannot buy. Pouring billions into longevity research becomes a rational strategy to secure more of it. NewLimit’s surging valuation and move into the clinic are the latest evidence that this endeavor is accelerating. Brian Armstrong’s leap from crypto exchanges to aging science reflects not just the ambitions of a tech founder, but a broader shift in how the world’s wealthiest are trying to rewrite the code of life itself.
